NCT05241405 (QISEIN) is a NA clinical trial of QISENG in Breast Cancer, sponsored by Centre Francois Baclesse.

Who is sponsoring NCT05241405?

NCT05241405 is sponsored by Centre Francois Baclesse.

What drugs are being tested in NCT05241405?

Interventions in NCT05241405: QISENG, PLACEBO.

What condition does NCT05241405 study?

NCT05241405 studies Breast Cancer, Fatigue.

Is NCT05241405 still recruiting?

NCT05241405 is currently recruiting now. Last updated 30 September 2024.

Last reviewed 2024-09-30 · How we verify

NCT05241405: QISEIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer - Randomized, Placebo-controlled, Double-blind Study

Recruiting now NA Last updated 30 September 2024

What this trial tests

NA trial testing QISENG in Breast Cancer in 354 participants. Currently enrolling.

Timeline

27 September 2022

Primary endpoint
1 September 2027

1 September 2027

Quick facts

Lead sponsor	Centre Francois Baclesse
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	354
Start date	27 September 2022
Primary completion	1 September 2027
Estimated completion	1 September 2027
Sites	10 locations across France

Drugs / interventions tested

QISENG
PLACEBO

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Fatigue — all drugs for Fatigue →

Sponsor

Centre Francois Baclesse — full company profile →

Who can join

18 and older, female only, with Breast Cancer or Fatigue. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fatigue score change [min :5; max:20]
Time frame: After 1 week and 4 weeks after the end of treatment (so 8 weeks of treatment)
The difference between the initial (inclusion) score and the best score based on EORTC QLQ-FA12 questionnaire (physical fatigue dimension) between assessments at 1 week (S9) and 4 weeks (S12) after the end of treatment) will be calculated

Sponsor's own description

This is a multicenter randomized trial in breast cancer patients reporting cancer-related fatigue to evaluate the efficacy and safety of Qiseng® based on extract of American ginseng combined with vitamin C from extract of Camu Camu berries

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A <i>Panax quinquefolius</i>-Based Preparation Prevents the Impact of 5-FU on Activity/Exploration Behaviors and Not on Cognitive Functions Mitigating Gut Microbiota and Inflammation in Mice.
Parment R, Dubois M, Desrues L, Mutel A, et al · · 2022 · cited 7× · PMID 36139563 · DOI 10.3390/cancers14184403

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Centre Francois Baclesse trials

Trials by the same sponsor.

NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05241405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
Last refreshed: 30 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05241405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing